NL-OMON24704招募中不适用
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U.
HOVO0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •* DLBCL or BCL-U, histologically confirmed according to the WHO classification 2008 with a MYC rearrangement as determined by FISH comprising:
- •- single hit (SH MYC+ lymphoma, not fulfilling the criteria for Burkitt Lymphoma ) or
排除标准
- •* All histopathological diagnoses other than DLBCL or BCL-U according to the WHO classification 2008, like Burkitt lymphoma, irrespective of the presence of MYC rearrangement
- •* Known history of indolent lymphoma. If during screening localization of an indolent lymphoma in the bone marrow biopsy is diagnosed, the patient is eligible.
研究者
相似试验
已完成
2 期
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U.Diffuse Large B Cell Lymophoma10025320NL-OMON47340HOVO82
进行中（未招募）
1 期
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCLMYC positive diffuse large B cell lymphoma and Burkitt lymphomaMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004943MedDRA version: 20.0Level: HLTClassification code 10006596Term: Burkitt's lymphomasSystem Organ Class: 100000004943EUCTR2014-002654-39-BEHOVON Foundation85
进行中（未招募）
1 期
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCLEUCTR2014-002654-39-NLHOVON Foundation85
进行中（未招募）
不适用
XINACT: To evaluate the benefit of specific drug combinations in reducing cancer tissue in the breast in women who have large breast cancers but confined to the breast and draining lymph glands.EUCTR2007-003221-25-GBnited Lincolnshire Hospitals NHS Trust120
已完成
不适用
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomasCancerISRCTN30851756VU University Medical Center (The Netherlands)200